Zyagnum is a biotechnology company that is revolutionizing the early detection of serious diseases. With their innovative EDIM-Technology, they aim to diagnose chronic health conditions before they even manifest, allowing for the best possible treatments and outcomes. Their mission is to transform early detection into true prevention for life-altering diseases like cancer, Alzheimer's, and diabetes.

The cornerstone of Zyagnum's approach is their EDIM® (Epitope Detection in Monocytes) platform technology, which leverages the body's immune system to detect abnormalities that may indicate the onset of illness. By analyzing macrophages for antigens, Zyagnum's immunological biopsy provides valuable context information and helps identify potential health issues at an early stage. Their breakthrough PanTum Detect® blood test has proven effective in early detection, with 82% of participants showing tumor-related immunological processes.

Zyagnum is dedicated to making their diagnostics simple, cost-effective, and minimally invasive to benefit as many people as possible. Through ongoing research projects in cancer diagnostics, burnout detection, Alzheimer's, and brain tumors, Zyagnum is committed to advancing the field of diagnostics and detecting tumors as early as possible. Contact Zyagnum today to learn more about their groundbreaking products, services, and clinical studies